Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis

The Lancet Oncology

Volumn 11, Issue 8, 2010, Pages 753-762

  De Roock, Wendy ^a   Claes, Bart ^a   Bernasconi, David ^b   De Schutter, Jef ^a   Biesmans, Bart ^a   Fountzilas, George ^c   Kalogeras, Konstantine T ^c   Kotoula, Vassiliki ^c   Papamichael, Demetris ^d   Laurent Puig, Pierre ^e   Penault Llorca, Frédérique ^f   Rougier, Philippe ^g   Vincenzi, Bruno ^h   Santini, Daniele ^h   Tonini, Giuseppe ^h   Cappuzzo, Federico ⁱ   Frattini, Milo ^j   Molinari, Francesca ^j   Saletti, Piercarlo ^k   De Dosso, Sara ^k   Martini, Miriam ^l   Bardelli, Alberto ^l,m   Siena, Salvatore ⁿ   Sartore Bianchi, Andrea ⁿ   Tabernero, Josep ^o   Macarulla, Teresa ^o   Di Fiore, Frédéric ^p,q   Gangloff, Alice Oden ^p,q   Ciardiello, Fortunato ^r   Pfeiffer, Per ^s   Qvortrup, Camilla ^s   Hansen, Tine Plato ^s   Van Cutsem, Eric ^t   Piessevaux, Hubert ^u   Lambrechts, Diether ^t   Delorenzi, Mauro ^u,v   Tejpar, Sabine ^s,t   more..

^a UNIVERSITY OF LEUVEN   (Belgium)

^b SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d Bank of Cyprus Group Oncology Centre   (Cyprus)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f UNIVERSITÉ CLERMONT AUVERGNE   (France)

^g HÔPITAL AMBROISE PARÉ   (France)

^h UNIVERSITY CAMPUS BIO MEDICO   (Italy)

ⁱ Ospedale Civile   (Italy)

^j INSTITUTE OF PATHOLOGY   (Switzerland)

^k SAN GIOVANNI HOSPITAL   (Switzerland)

^l UNIVERSITY OF TURIN   (Italy)

^m FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

ⁿ OSPEDALE NIGUARDA CA GRANDA   (Italy)

^o HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^p ROUEN UNIVERSITY HOSPITAL   (France)

^q INSERM   (France)

^r SECOND UNIVERSITY OF NAPLES   (Italy)

^s ODENSE UNIVERSITY HOSPITAL   (Denmark)

^t UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^u CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^v LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; CETUXIMAB; K RAS PROTEIN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE ALPHA; PROTEIN N RAS; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DNA DETERMINATION; DRUG EFFICACY; DRUG SAFETY; EXON; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MUTATION RATE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DOMAIN; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, RAS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; ROC CURVE; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77955277111     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70130-3     Document Type: Article

References (34)

1. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-345.
2. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:1626-1634.
3. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 35:757-765.
4. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009, 27:2091-2096.
5. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 2009, 4:e7287.
6. Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009, 27:5924-5930.
7. De Roock W, Lambrechts D, Tejpar S K-ras mutations and cetuximab in colorectal cancer. N Engl J Med 2009, 360:834.
8. Piessevaux H, Buyse M, De Roock W, et al. Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial). Ann Oncol 2009, 20:1375-1382.
9. Catalogue of somatic mutations in cancer Wellcome Trust Sanger Institute, (accessed Oct 15, 2008). http://www.sanger.ac.uk/genetics/CGP/cosmic.
10. Downward J Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003, 3:11-22.
11. Hothorn T, Hornik K, Zeileis A Unbiased recursive partitioning: a conditional inference framework. J Comput Graph Stat 2006, 15:651-674.
12. Ogino S, Katsuhiko N, Gregory J, et al. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol 2009, 27:1477-1484.
13. Barault L, Veyrie N, Jooste V, et al. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 2008, 122:2255-2259.
14. Souglakos J, Philips J, Wang R, et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer 2009, 101:465-472.
15. Zhao L, Vogt PK Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci USA 2008, 105:2652-2657.
16. Kalinsky K, Jacks LM, Heguy A, et al. PIK3CA mutation associates with improved outcome in breast cancer. Clin Canc Res 2009, 15:5049-5059.
17. Lai Y-L, Mau B-L, Cheng W-H, Chen H-M, Chiu H-H, Tzen C-Y PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients. Ann Surg Oncol 2008, 15:1064-1069.
18. Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009, 6:519-527.
19. Bardelli A, Siena S Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010, 28:1254-1261.
20. Loupakis F, Ruzzo A, Cremolini C, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009, 101:715-721.
21. Sartore-Bianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009, 69:1851-1857.
22. Prenen H, De Schutter J, Jacobs B, et al. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 2009, 15:3184-3188.
23. Smalley KS, Xiao M, Villanueva J, et al. CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene 2009, 28:85-94.
24. Richman SD, Seymour MT, Chambers P, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009, 27:5931-5937.
25. Van Cutsem E, Lang I, Folprecht G, et al. Cetuximab plus FOLFIRI: final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome. J Clin Oncol 2010, 28(suppl). abstr 3570.
26. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial. J Clin Oncol 2010, 28:466-474.
27. Peeters M, Oliner KS, Parker A, et al. Use of massively parallel, next-generation sequencing to identify gene mutations beyond KRAS that predict response to panitumumab in a randomized, phase 3, monotherapy study of metastatic colorectal cancer (mCRC). 2010 American Association for Cancer Research 101st Annual Meeting, Washington, DC, USA; April 17-21: abstr LB-174.
28. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005, 6:279-286.
29. Personeni N, Fieuws S, Piessevaux H, et al. Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with Cetuximab: a fluorescent in situ hybridization study. Clin Cancer Res 2008, 14:5869-5876.
30. Jacobs B, De Roock W, Piessevaux H, et al. Amphiregulin and Epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 2009, 27:5068-5074.
31. Tabernero J, Cervantes A, Rivera F, et al. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. J Clin Oncol 2010, 28:1181-1189.
32. Zhang W, Gordon M, Schultheis AM, et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007, 25:3712-3718.
33. Lurje G, Nagashima F, Zhang W, et al. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Clin Cancer Res 2008, 14:7884-7895.
34. Bibeau F, Lopez-Crapez E, Di Fiore F, et al. Impact of FcγRIIa-FcγRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009, 27:1122-1129.